Switch to:
Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.60
NYSE:PFE's Cash to Debt is ranked lower than
71% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.46 vs. NYSE:PFE: 0.60 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:PFE' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 0.90 Max: 3.47
Current: 0.6
0.22
3.47
Equity to Asset 0.39
NYSE:PFE's Equity to Asset is ranked lower than
80% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. NYSE:PFE: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:PFE' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.47 Max: 0.66
Current: 0.39
0.39
0.66
Interest Coverage 19.27
NYSE:PFE's Interest Coverage is ranked lower than
54% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.68 vs. NYSE:PFE: 19.27 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.24  Med: 10.79 Max: 24.84
Current: 19.27
5.24
24.84
F-Score: 6
Z-Score: 2.42
M-Score: -2.64
WACC vs ROIC
8.50%
11.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 24.19
NYSE:PFE's Operating margin (%) is ranked higher than
86% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. NYSE:PFE: 24.19 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:PFE' s Operating margin (%) Range Over the Past 10 Years
Min: 13.89  Med: 22.51 Max: 32.43
Current: 24.19
13.89
32.43
Net-margin (%) 14.25
NYSE:PFE's Net-margin (%) is ranked higher than
77% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. NYSE:PFE: 14.25 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:PFE' s Net-margin (%) Range Over the Past 10 Years
Min: 12.18  Med: 17.17 Max: 42.65
Current: 14.25
12.18
42.65
ROE (%) 10.32
NYSE:PFE's ROE (%) is ranked higher than
61% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. NYSE:PFE: 10.32 )
Ranked among companies with meaningful ROE (%) only.
NYSE:PFE' s ROE (%) Range Over the Past 10 Years
Min: 9.29  Med: 12.22 Max: 28.2
Current: 10.32
9.29
28.2
ROA (%) 4.20
NYSE:PFE's ROA (%) is ranked higher than
52% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.85 vs. NYSE:PFE: 4.20 )
Ranked among companies with meaningful ROA (%) only.
NYSE:PFE' s ROA (%) Range Over the Past 10 Years
Min: 4.05  Med: 6.90 Max: 16.63
Current: 4.2
4.05
16.63
ROC (Joel Greenblatt) (%) 54.02
NYSE:PFE's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.64 vs. NYSE:PFE: 54.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:PFE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.57  Med: 57.28 Max: 85.94
Current: 54.02
40.57
85.94
Revenue Growth (3Y)(%) -3.40
NYSE:PFE's Revenue Growth (3Y)(%) is ranked lower than
76% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. NYSE:PFE: -3.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:PFE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.8  Med: 6.15 Max: 19.2
Current: -3.4
-3.8
19.2
EPS Growth (3Y)(%) 12.50
NYSE:PFE's EPS Growth (3Y)(%) is ranked higher than
59% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. NYSE:PFE: 12.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:PFE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.8  Med: 3.60 Max: 90.5
Current: 12.5
-26.8
90.5
» NYSE:PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

PFE Guru Trades in Q2 2015

Ray Dalio 79,108 sh (New)
Kyle Bass 63,675 sh (New)
Jeremy Grantham 5,991,393 sh (+18003.62%)
John Keeley 129,055 sh (+30.77%)
Murray Stahl 62,776 sh (+3.34%)
John Buckingham 73,071 sh (+2.56%)
Ken Fisher 31,816,749 sh (+1.95%)
Barrow, Hanley, Mewhinney & Strauss 55,354,855 sh (+0.50%)
Richard Pzena 2,159,818 sh (+0.01%)
Prem Watsa 235,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
T Rowe Price Equity Income Fund 12,737,115 sh (unchged)
Vanguard Health Care Fund 19,395,622 sh (unchged)
Louis Moore Bacon 800,000 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
Steven Cohen 2,500,000 sh (unchged)
Ruane Cunniff 10,967 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Mairs and Power 2,351,483 sh (-0.51%)
David Dreman 24,926 sh (-1.10%)
Charles Brandes 6,054,883 sh (-1.12%)
Diamond Hill Capital 10,234,918 sh (-1.89%)
Kahn Brothers 1,774,875 sh (-2.00%)
Dodge & Cox 45,234,031 sh (-3.30%)
Mario Gabelli 819,901 sh (-8.54%)
Manning & Napier Advisors, Inc 793,722 sh (-9.43%)
Jeff Auxier 86,322 sh (-12.74%)
Pioneer Investments 4,669,110 sh (-17.68%)
First Eagle Investment 4,315,476 sh (-18.06%)
Jim Simons 2,081,041 sh (-20.64%)
RS Investment Management 1,955,985 sh (-24.78%)
NWQ Managers 4,372,936 sh (-26.23%)
Joel Greenblatt 1,024,564 sh (-48.07%)
Paul Tudor Jones 15,600 sh (-98.63%)
» More
Q3 2015

PFE Guru Trades in Q3 2015

Louis Moore Bacon 350,000 sh (New)
Leon Cooperman 4,830,595 sh (New)
John Burbank 1,292,832 sh (New)
Lee Ainslie 6,937,928 sh (New)
Ray Dalio 345,708 sh (+337.01%)
Paul Tudor Jones 28,300 sh (+81.41%)
First Eagle Investment 6,090,294 sh (+41.13%)
Mairs and Power 3,063,915 sh (+30.30%)
Pioneer Investments 5,617,211 sh (+20.31%)
Jeremy Grantham 6,293,591 sh (+5.04%)
Murray Stahl 65,741 sh (+4.72%)
Ruane Cunniff 11,302 sh (+3.05%)
Joel Greenblatt 1,047,861 sh (+2.27%)
Diamond Hill Capital 10,380,922 sh (+1.43%)
Ken Fisher 31,926,879 sh (+0.35%)
Dodge & Cox 45,266,436 sh (+0.07%)
Ronald Muhlenkamp 38,409 sh (unchged)
David Carlson 300,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Jeff Auxier 86,322 sh (unchged)
Steven Cohen 2,200,000 sh (unchged)
Richard Pzena 2,159,818 sh (unchged)
NWQ Managers 217,300 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Signature Select Canadian Fund Sold Out
Jim Simons Sold Out
Kyle Bass Sold Out
NWQ Managers 4,357,477 sh (-0.35%)
John Buckingham 72,589 sh (-0.66%)
T Rowe Price Equity Income Fund 12,599,315 sh (-1.08%)
John Keeley 126,755 sh (-1.78%)
Barrow, Hanley, Mewhinney & Strauss 54,274,453 sh (-1.95%)
Charles Brandes 5,863,701 sh (-3.16%)
Manning & Napier Advisors, Inc 757,703 sh (-4.54%)
Kahn Brothers 1,671,039 sh (-5.85%)
RS Investment Management 1,819,885 sh (-6.96%)
Mario Gabelli 730,005 sh (-10.96%)
Vanguard Health Care Fund 12,550,992 sh (-35.29%)
David Dreman 6,443 sh (-74.15%)
» More
Q4 2015

PFE Guru Trades in Q4 2015

Alan Fournier 3,027,040 sh (New)
Andreas Halvorsen 7,424,690 sh (New)
David Tepper 2,412,250 sh (New)
John Paulson 632,700 sh (New)
Jana Partners 9,168,818 sh (New)
Jim Simons 7,985,341 sh (New)
Lee Ainslie 11,298,953 sh (+62.86%)
Pioneer Investments 8,180,008 sh (+45.62%)
Ruane Cunniff 14,850 sh (+31.39%)
Mairs and Power 3,897,329 sh (+27.20%)
Ray Dalio 434,408 sh (+25.66%)
Paul Tudor Jones 34,900 sh (+23.32%)
T Rowe Price Equity Income Fund 14,525,000 sh (+15.28%)
John Buckingham 76,884 sh (+5.92%)
Diamond Hill Capital 10,721,361 sh (+3.28%)
Ken Fisher 32,334,417 sh (+1.28%)
Murray Stahl 65,941 sh (+0.30%)
Richard Pzena 2,161,593 sh (+0.08%)
David Carlson 300,000 sh (unchged)
George Soros 1,290,000 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
Robert Bruce 455,332 sh (unchged)
David Dreman Sold Out
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Jeff Auxier 86,224 sh (-0.11%)
Barrow, Hanley, Mewhinney & Strauss 53,862,996 sh (-0.76%)
Manning & Napier Advisors, Inc 735,031 sh (-2.99%)
Mario Gabelli 706,956 sh (-3.16%)
Charles Brandes 5,639,537 sh (-3.82%)
Jeremy Grantham 5,978,092 sh (-5.01%)
Kahn Brothers 1,569,873 sh (-6.05%)
RS Investment Management 1,634,205 sh (-10.20%)
Prem Watsa 210,000 sh (-10.64%)
Vanguard Health Care Fund 8,872,226 sh (-29.31%)
John Keeley 77,749 sh (-38.66%)
NWQ Managers 1,967,718 sh (-54.84%)
Leon Cooperman 1,295,600 sh (-73.18%)
John Burbank 161,742 sh (-87.49%)
Dodge & Cox 2,243,178 sh (-95.04%)
First Eagle Investment 135,661 sh (-97.77%)
» More
Q1 2016

PFE Guru Trades in Q1 2016

Murray Stahl 68,472 sh (+3.84%)
T Rowe Price Equity Income Fund 14,730,900 sh (+1.42%)
Manning & Napier Advisors, Inc 726,260 sh (-1.19%)
Ken Fisher 31,746,148 sh (-1.82%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pfizer Inc

Diamond Hill Capital Comments on Pfizer Inc - Jul 25, 2014

Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Pfizer Inc

Pfizer-Allergan Merger Collapse Hurts Some Funds But Is Boosting Others Allergan's price sank but Pfizer's actually rose significantly following the merger agreement failure, a boost for long-term holders
When Pfizer Inc. (NYSE:PFE) and Allergan Plc (NYSE:AGN) announced their proposed merger deal collapsed on April 6, so too did the hopes of several influential hedge fund managers who staked much capital on its success, but some investors have seen benefits. Read more...
2 Major Mergers Come to End After Tough Stance From Regulators Treasury and Justice Department put the brakes on health care and oil deals
Two planned mega-mergers came to an end Wednesday following steps from the federal government to prevent deals that may threaten market competition. Read more...
Jim Simons Purchases Stake in Pfizer Pfizer has high operating margin compared to peers
Guru Jim Simons (Trades, Portfolio) is an American mathematician, hedge fund manager and philanthropist. Simons founded the hedge fund Renaissance Technologies in 1982, which he ran for 28 years before retiring at the end of 2009, though he still serves as non-executive chairman. Renaissance Technologies currently owns 3,254 stocks with a total value of $45.9 billion. Read more...
Louis Moore Bacon Sells JPMorgan, Pfizer The guru's largest 4th-quarter transactions
Louis Moore Bacon (Trades, Portfolio) is an American hedge fund manager and trader who uses a global macro strategy to invest in the markets. Bacon has been in the top 20 of Top 100 money earners since the 1990s. He is considered one of the top 100 traders of the 20th century, and the following are his most heavily weighted trades during the fourth quarter of 2015. Read more...
Jana Partners Acquires Stakes in Pfizer and Valeant Guru purchases 17 new stakes in 4th quarter
Jana Partners (Trades, Portfolio) acquired 17 new stakes in the fourth quarter, and more than half had impacts on the guru’s portfolio of 1% or greater. Read more...
Dodge & Cox Trims Stakes in Pfizer, GE, eBay, Microsoft Guru adds to holdings in American Express, Twenty-First Century Fox
Dodge & Cox added three new stakes to its portfolio in the fourth quarter, but the transactions that had the greatest impact were the guru's sales of portions of existing stakes. Read more...
Mairs and Power Boosts Holdings in Hormel Foods Guru rearranges its 20 most-valuable stakes in 4th quarter
Mairs and Power (Trades, Portfolio) had an interesting fourth quarter, adding and reducing holdings in familiar and not-so-familiar names and rearranging its 20 most-valuable stakes. Read more...
Jana Partners Buys Pfizer, AIG, Microsoft Event-driven investing firm's largest 4th quarter trades
Jana Partners is an investment manager specializing in event-driven investing founded in 2001 by Barry Rosenstein, Jana’s managing partner and co-portfolio manager. Jana typically applies a fundamental value discipline to identify undervalued companies that have one or more specific catalysts to unlock value. The following were some of its fourth quarter trades. Read more...
Alan Fournier Invests in Oil and Gas Company Kinder Morgan Guru also invests in Pfizer in 4th quarter
Alan Fournier (Trades, Portfolio) of Pennant Capital made only two new buys in the fourth quarter, but one of those buys was his most noteworthy deal of the quarter. Read more...
Alan Fournier Buys Kinder Morgan, Pfizer The investor updated his fourth quarter portfolio
Alan Fournier (Trades, Portfolio) manages Pennant Master Fund, Pennant Windward Master Fund, Broadway Gate Master Fund Ltd. and Pennant General Partner LLC. He manages a portfolio composed of 38 holdings, and during the fourth quarter he raised his stake in six stocks and acquired two new positions. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.67
PFE's P/E(ttm) is ranked lower than
53% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.10 vs. PFE: 29.67 )
Ranked among companies with meaningful P/E(ttm) only.
PFE' s P/E(ttm) Range Over the Past 10 Years
Min: 7.67  Med: 16.06 Max: 29.91
Current: 29.67
7.67
29.91
Forward P/E 13.44
PFE's Forward P/E is ranked higher than
57% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.85 vs. PFE: 13.44 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.67
PFE's PE(NRI) is ranked lower than
54% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.01 vs. PFE: 29.67 )
Ranked among companies with meaningful PE(NRI) only.
PFE' s PE(NRI) Range Over the Past 10 Years
Min: 9.77  Med: 19.06 Max: 29.91
Current: 29.67
9.77
29.91
Price/Owner Earnings (ttm) 14.76
PFE's Price/Owner Earnings (ttm) is ranked higher than
81% of the 261 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.99 vs. PFE: 14.76 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PFE' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.32  Med: 10.34 Max: 28.19
Current: 14.76
5.32
28.19
P/B 3.12
PFE's P/B is ranked lower than
53% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.94 vs. PFE: 3.12 )
Ranked among companies with meaningful P/B only.
PFE' s P/B Range Over the Past 10 Years
Min: 1.32  Med: 2.40 Max: 3.32
Current: 3.12
1.32
3.32
P/S 4.34
PFE's P/S is ranked lower than
65% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.78 vs. PFE: 4.34 )
Ranked among companies with meaningful P/S only.
PFE' s P/S Range Over the Past 10 Years
Min: 1.71  Med: 3.49 Max: 4.75
Current: 4.34
1.71
4.75
PFCF 14.87
PFE's PFCF is ranked higher than
72% of the 194 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.93 vs. PFE: 14.87 )
Ranked among companies with meaningful PFCF only.
PFE' s PFCF Range Over the Past 10 Years
Min: 5.02  Med: 12.87 Max: 17.52
Current: 14.87
5.02
17.52
POCF 13.65
PFE's POCF is ranked higher than
64% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. PFE: 13.65 )
Ranked among companies with meaningful POCF only.
PFE' s POCF Range Over the Past 10 Years
Min: 4.55  Med: 11.46 Max: 15.67
Current: 13.65
4.55
15.67
EV-to-EBIT 17.40
PFE's EV-to-EBIT is ranked higher than
56% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.82 vs. PFE: 17.40 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 13.80 Max: 19.6
Current: 17.4
6.7
19.6
EV-to-EBITDA 12.49
PFE's EV-to-EBITDA is ranked higher than
66% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. PFE: 12.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.30 Max: 13.1
Current: 12.49
4.9
13.1
PEG 4.07
PFE's PEG is ranked lower than
71% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. PFE: 4.07 )
Ranked among companies with meaningful PEG only.
PFE' s PEG Range Over the Past 10 Years
Min: 0.97  Med: 2.31 Max: 32.12
Current: 4.07
0.97
32.12
Shiller P/E 18.39
PFE's Shiller P/E is ranked higher than
86% of the 140 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.65 vs. PFE: 18.39 )
Ranked among companies with meaningful Shiller P/E only.
PFE' s Shiller P/E Range Over the Past 10 Years
Min: 9.05  Med: 16.36 Max: 25.62
Current: 18.39
9.05
25.62
Current Ratio 1.62
PFE's Current Ratio is ranked lower than
69% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. PFE: 1.62 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.65 Max: 3.18
Current: 1.62
1.1
3.18
Quick Ratio 1.34
PFE's Quick Ratio is ranked lower than
63% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. PFE: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.43 Max: 2.86
Current: 1.34
0.84
2.86
Days Inventory 245.45
PFE's Days Inventory is ranked lower than
89% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.44 vs. PFE: 245.45 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 236.05 Max: 344.63
Current: 245.45
185.33
344.63
Days Sales Outstanding 61.09
PFE's Days Sales Outstanding is ranked higher than
62% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.18 vs. PFE: 61.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.79  Med: 72.27 Max: 106.89
Current: 61.09
63.79
106.89
Days Payable 136.96
PFE's Days Payable is ranked higher than
80% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.90 vs. PFE: 136.96 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 100.54 Max: 179.46
Current: 136.96
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.45
PFE's Dividend Yield is ranked higher than
83% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. PFE: 3.45 )
Ranked among companies with meaningful Dividend Yield only.
PFE' s Dividend Yield Range Over the Past 10 Years
Min: 2.5  Med: 3.65 Max: 10.4
Current: 3.45
2.5
10.4
Dividend Payout 1.01
PFE's Dividend Payout is ranked lower than
75% of the 365 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. PFE: 1.01 )
Ranked among companies with meaningful Dividend Payout only.
PFE' s Dividend Payout Range Over the Past 10 Years
Min: 0.3  Med: 0.54 Max: 10.67
Current: 1.01
0.3
10.67
Dividend Growth (3y) 9.10
PFE's Dividend Growth (3y) is ranked higher than
55% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. PFE: 9.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
PFE' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -14.7  Med: 14.45 Max: 22.6
Current: 9.1
-14.7
22.6
Forward Dividend Yield 3.64
PFE's Forward Dividend Yield is ranked higher than
86% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 3.64 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.77
PFE's Yield on cost (5-Year) is ranked higher than
81% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. PFE: 4.77 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PFE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.46  Med: 5.05 Max: 14.38
Current: 4.77
3.46
14.38
3-Year Average Share Buyback Ratio 6.50
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.30 vs. PFE: 6.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.9  Med: -1.05 Max: 6.5
Current: 6.5
-17.9
6.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.05
PFE's Price/Projected FCF is ranked higher than
86% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.83 vs. PFE: 1.05 )
Ranked among companies with meaningful Price/Projected FCF only.
PFE' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.05 Max: 8.57
Current: 1.05
0.53
8.57
Price/Median PS Value 1.24
PFE's Price/Median PS Value is ranked lower than
55% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. PFE: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
PFE' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.49  Med: 1.21 Max: 3.41
Current: 1.24
0.49
3.41
Price/Peter Lynch Fair Value 4.51
PFE's Price/Peter Lynch Fair Value is ranked lower than
87% of the 174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. PFE: 4.51 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PFE' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.18  Med: 2.35 Max: 34.03
Current: 4.51
1.18
34.03
Earnings Yield (Greenblatt) (%) 5.78
PFE's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. PFE: 5.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PFE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.1  Med: 7.30 Max: 14.9
Current: 5.78
5.1
14.9
Forward Rate of Return (Yacktman) (%) 12.38
PFE's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.27 vs. PFE: 12.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PFE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 8.3  Med: 14.50 Max: 22.8
Current: 12.38
8.3
22.8

More Statistics

Revenue(Mil) $48851
EPS $ 1.11
Beta1.02
Short Percentage of Float2.42%
52-Week Range $28.25 - 36.46
Shares Outstanding(Mil)6184.14

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 55,709 61,916 67,672
EPS($) 2.23 2.45 2.80
EPS without NRI($) 2.23 2.45 2.80

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, PFZ.UK,
Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.
» More Articles for PFE

Headlines

Articles On GuruFocus.com
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Wilbur Ross Denounces Anti-Business 'Terrible Populist Sentiment' on CNBC Apr 07 2016 
2 Major Mergers Come to End After Tough Stance From Regulators Apr 07 2016 
Time To Buy Allergan Apr 06 2016 
Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
Jim Simons Purchases Stake in Pfizer Mar 31 2016 
Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
Louis Moore Bacon Sells JPMorgan, Pfizer Mar 25 2016 

More From Other Websites
Pfizer gets vote of confidence Apr 29 2016
Business events scheduled for the coming week Apr 28 2016
Business events scheduled for the coming week Apr 28 2016
Shareholders criticize Pfizer after scrapped Allergan deal Apr 28 2016
Shareholders criticize Pfizer after scrapped Allergan deal Apr 28 2016
Pfizer Hosts Annual Meeting of Shareholders Apr 28 2016
Pfizer Hosts Annual Meeting of Shareholders Apr 28 2016
Ohio Medicaid gets $25M from Pfizer drug discount settlement Apr 28 2016
Ohio Medicaid gets $25M from Pfizer drug discount settlement Apr 28 2016
Pfizer (PFE) to Report Q1 Earnings: Will the Stock Surprise? Apr 28 2016
Advocates hold NYC protest over price of pneumonia vaccine Apr 27 2016
Advocates hold NYC protest over price of pneumonia vaccine Apr 27 2016
Is Allergan On The Prowl For New Deals? Apr 27 2016
Pfizer to pay $785 mn for overcharging US government on drugs Apr 27 2016
Pfizer finalizes $785M settlement to resolve allegations of underpaying Medicaid rebates Apr 27 2016
Feds finalize $98M payment to whistleblowers in Pfizer Medicaid case Apr 27 2016
Pfizer to pay $785 million for overcharging US government on drugs Apr 27 2016
Pfizer agrees to $785M settlement in drug discount case Apr 27 2016
Pfizer agrees to $785M settlement in drug discount case Apr 27 2016
Pfizer to pay $784.6 million to resolve Wyeth false claims lawsuit Apr 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK